Some pretty exciting research has come about regarding GLP-1 receptor agonists (think drugs like Ozempic or Wegovy). Researchers studying large populations of women found that GLP-1 receptor agonists were associated with a lower incidence of HR+/HER2− breast cancer, improved overall survival, and lower recurrence rates within certain breast cancer populations. GLP-1 stands for “glucagon-like peptide-1”…